Back to top

Atossa Therapeutics: Strategic Advancements and Strong Financial Position Signal Promising Future

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Atossa Therapeutics, retaining the price target of $4.00. Jason McCarthy has given...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Atossa Genetics Inc. (ATOS)